Shots:

• The companies reported the initiation of P-I/II trial to evaluate the safety- tolerability- and immunogenicity of MRT5500 (1 or 2doses given 21 days apart) vs PBO in ~415 healthy adults aged ≥18yrs. with its expected interim results in Q3’21
• The study will evaluate three different dose levels of MRT5500 (15/45/135µg). The preclinical data of MRT5500 showed induction of high neutralizing antibody levels in two immunizations of the mRNA vaccine are comparable to the upper range in infected humans
• The ongoing preclinical studies will continue to evaluate MRT5500 as well as additional mRNA candidates against emerging SARS-CoV-2 variants

 ­ Ref: GlobeNewswire | Image: Bloomberg